Alcoholic Hepatitis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：56頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Alcoholic Hepatitis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Alcoholic Hepatitis - Pipeline Review, H1 2014’, provides an overview of the Alcoholic Hepatitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Alcoholic Hepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcoholic Hepatitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Alcoholic Hepatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Alcoholic Hepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alcoholic Hepatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Alcoholic Hepatitis - Pipeline Review, H1 2014’, provides an overview of the Alcoholic Hepatitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Alcoholic Hepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcoholic Hepatitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Alcoholic Hepatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Alcoholic Hepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alcoholic Hepatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Alcoholic Hepatitis Overview 6
Therapeutics Development 7
Pipeline Products for Alcoholic Hepatitis - Overview 7
Pipeline Products for Alcoholic Hepatitis - Comparative Analysis 8
Alcoholic Hepatitis - Therapeutics under Development by Companies 9
Alcoholic Hepatitis - Therapeutics under Investigation by Universities/Institutes 11
Alcoholic Hepatitis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Alcoholic Hepatitis - Products under Development by Companies 14
Alcoholic Hepatitis - Products under Investigation by Universities/Institutes 15
Alcoholic Hepatitis - Companies Involved in Therapeutics Development 16
Immuron Limited 16
Conatus Pharmaceuticals Inc. 17
Intercept Pharmaceuticals, Inc. 18
Alfact Innovation 19
Generon (Shanghai) Corporation Ltd. 20
Alcoholic Hepatitis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 25
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
obeticholic acid - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
emricasan - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
IMM-124E - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ALF-5755 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
F-652 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GRI-0621 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Antibody Drug For Hepatic Disease - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Alcoholic Hepatitis - Recent Pipeline Updates 46
Alcoholic Hepatitis - Product Development Milestones 53
Featured News & Press Releases 53
Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients 53
Sep 10, 2013: Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56
List of Tables
Number of Products under Development for Alcoholic Hepatitis, H1 2014 7
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Alcoholic Hepatitis - Pipeline by Immuron Limited, H1 2014 16
Alcoholic Hepatitis - Pipeline by Conatus Pharmaceuticals Inc., H1 2014 17
Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2014 18
Alcoholic Hepatitis - Pipeline by Alfact Innovation, H1 2014 19
Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Stage and Target, H1 2014 24
Number of Products by Stage and Mechanism of Action, H1 2014 27
Number of Products by Stage and Route of Administration, H1 2014 29
Number of Products by Stage and Molecule Type, H1 2014 31
Alcoholic Hepatitis Therapeutics - Recent Pipeline Updates, H1 2014 46
List of Figures
Number of Products under Development for Alcoholic Hepatitis, H1 2014 7
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 22
Number of Products by Stage and Top 10 Target, H1 2014 23
Number of Products by Top 10 Mechanism of Action, H1 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 26
Number of Products by Top 10 Route of Administration, H1 2014 28
Number of Products by Stage and Top 10 Route of Administration, H1 2014 29
Number of Products by Top 10 Molecule Type, H1 2014 30
Number of Products by Stage and Top 10 Molecule Type, H1 2014 31
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Alcoholic Hepatitis Overview 6
Therapeutics Development 7
Pipeline Products for Alcoholic Hepatitis - Overview 7
Pipeline Products for Alcoholic Hepatitis - Comparative Analysis 8
Alcoholic Hepatitis - Therapeutics under Development by Companies 9
Alcoholic Hepatitis - Therapeutics under Investigation by Universities/Institutes 11
Alcoholic Hepatitis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Alcoholic Hepatitis - Products under Development by Companies 14
Alcoholic Hepatitis - Products under Investigation by Universities/Institutes 15
Alcoholic Hepatitis - Companies Involved in Therapeutics Development 16
Immuron Limited 16
Conatus Pharmaceuticals Inc. 17
Intercept Pharmaceuticals, Inc. 18
Alfact Innovation 19
Generon (Shanghai) Corporation Ltd. 20
Alcoholic Hepatitis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 25
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
obeticholic acid - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
emricasan - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
IMM-124E - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ALF-5755 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
F-652 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GRI-0621 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Antibody Drug For Hepatic Disease - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Alcoholic Hepatitis - Recent Pipeline Updates 46
Alcoholic Hepatitis - Product Development Milestones 53
Featured News & Press Releases 53
Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients 53
Sep 10, 2013: Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56
List of Tables
Number of Products under Development for Alcoholic Hepatitis, H1 2014 7
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Alcoholic Hepatitis - Pipeline by Immuron Limited, H1 2014 16
Alcoholic Hepatitis - Pipeline by Conatus Pharmaceuticals Inc., H1 2014 17
Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2014 18
Alcoholic Hepatitis - Pipeline by Alfact Innovation, H1 2014 19
Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Stage and Target, H1 2014 24
Number of Products by Stage and Mechanism of Action, H1 2014 27
Number of Products by Stage and Route of Administration, H1 2014 29
Number of Products by Stage and Molecule Type, H1 2014 31
Alcoholic Hepatitis Therapeutics - Recent Pipeline Updates, H1 2014 46
List of Figures
Number of Products under Development for Alcoholic Hepatitis, H1 2014 7
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 22
Number of Products by Stage and Top 10 Target, H1 2014 23
Number of Products by Top 10 Mechanism of Action, H1 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 26
Number of Products by Top 10 Route of Administration, H1 2014 28
Number of Products by Stage and Top 10 Route of Administration, H1 2014 29
Number of Products by Top 10 Molecule Type, H1 2014 30
Number of Products by Stage and Top 10 Molecule Type, H1 2014 31
